Redeye provides an initial take on Genovis’ Q3 report. We argue that it is a relatively weak report as the sales growth was only 10% (low for Genovis). However, the third quarter is a seasonally weaker quarter for the company. We continue to see a strong outlook for Genovis as things get back to normal and with a potential follow-up order in Bioprocess in the coming months, we continue to see the stock as a compelling investment.
Lähde: Finwire News